ROYAL OAK — OncoCell MDx, an immunogenomics company developing new, noninvasive molecular diagnostic assays, announced that Kirk Wojno, M.D., has joined the company’s leadership team as its chief medical officer.
Wojno, a renowned urologic pathologist and expert in prostate biopsy interpretation, joins an expanding, experienced executive team. OncoCell MDx also recently announced the appointments of Mark McDonough as president and CEO and Christopher Thibodeau as COO.
“OncoCell is in an exciting phase of growth. We are moving toward commercialization of our first immunogenomics test for prostate cancer, and we are continuing to develop our pipeline of noninvasive tests for other cancers and diseases,” said McDonough. “Dr. Wojno brings a wealth of knowledge of the company and the space, an illustrious reputation, expert knowledge of anatomic and molecular pathology, and deep experience running clinical affairs and laboratory operations.”
Wojno is the former head of urologic pathology at the University of Michigan, at Ascension Health System, and at national Ameripath Laboratories. He has more than 30 years in medical practice and most recently served as the chief of pathology and laboratory services and director of clinical research for Comprehensive Urology in Royal Oak, one of the largest urology group practices in the United States. While at Johns Hopkins University, Wojno trained with the Brady Institute’s Jonathan Epstein, M.D. an internationally recognized authority in uropathology. Wojno received his medical degree from Wayne State University School of Medicine.
“Screening, diagnosis and management of prostate cancer continues to be challenging due to tumor heterogeneity and complexity,” Wojno said. “As a practicing pathologist over the past three decades, I’m delighted to work with OncoCell in addressing a significant need to improve patient selection for active surveillance and to provide a noninvasive method for annual monitoring. Our goal is to help reduce overtreatment of indolent disease along with patient anxiety. I am equally excited about the promise this technology offers across a broad spectrum of diagnostic indications, from cancer, cardiovascular, infectious and neurodegenerative disease, to immune- and kidney-related diseases.”
More at https://oncocellmdx.com/.